UbiVac is a clinical stage biotechnology company engaged in the research and development of therapeutic vaccines to combat cancer and infectious diseases.

Founded in Portland, OR in 2005 as a spinout of the Robert W. Franz Cancer Research Center within the Earle A. Chiles Research Institute, at Providence Portland Medical Center, UbiVac continues to build upon the groundbreaking research being developed in the region.

In 2011, UbiVac in cooperation with Oregon Health & Science University created UbiVac-CMV Inc., to license a disabled cytomegalovirus (CMV) vector technology for use as a vaccine. This technology is actively being developed in collaboration with our research partners.

Latest News

Providence Cancer spinoff inks agreement with major pharma company

Portland Business Journal September 11, 2015

The vaccine, called DPV-001, stimulates a patient’s own immune system in the fight against invading tumors. It’s designed for patients who have gone through…

Read More

Providence will test its new lung cancer vaccine at Mayo, other top clinics

Portland Business Journal September 1, 2015

Providence Cancer Center has embarked on a new lung cancer vaccine trial encompassing multiple sites around the country, including the Mayo Clinic.

Read More